Findings

What do systematic reviews say?

7 questions · 7 findings · 5 reviews · Metabolic and Endocrine Disorders · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

Surgery vs Pharmacological therapy

Health‐related quality of life Mean AcroQoL score (0‐100) · adults with growth‐hormone secreting pituitary adenomas

Surgery alone showed no clear difference in health‐related quality of life Mean AcroQoL score (0‐100) compared with pharmacological therapy alone (low certainty).

1 finding from 1 review

Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting pituitary… 2024 · Cochrane Headline outcomes only
MD 10
1 study · 22 participants
Low

Short‐acting insulin analogues vs regular human insulin

Macrovascular or microvascular complications

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting insulin analogues vs regular human insulin

Macrovascular complications

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intensive glycaemic control vs conventional glucose control

Macrovascular complications · persons with type 1 diabetes mellitus

1 finding from 1 review

Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus

The intervention may leads to lower non‐fatal macrovascular outcomes 1. Composite a. Intervention vs… (low certainty).

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
RR 0.67 [0.48, 0.93]
1 study · 3 participants
Low

Intervention not reported

Macrovascular outcomes · participants with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal myocardial infarction Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

The intervention showed no clear difference in non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal… (low certainty).

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
RR 1.08 [0.81, 1.45]
1 study · 2 participants
Low